Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,014 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Machine-learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR-15).
Boulenger de Hauteclocque A, Ferrer L, Ambrosetti D, Ricard S, Bigot P, Bensalah K, Henon F, Doumerc N, Méjean A, Verkarre V, Dariane C, Larré S, Champy C, de La Taille A, Bruyère F, Rouprêt M, Paparel P, Droupy S, Fontenil A, Patard JJ, Durand X, Waeckel T, Lang H, Lebâcle C, Guy L, Pignot G, Durand M, Long JA, Charles T, Xylinas E, Boissier R, Yacoub M, Colin T, Bernhard JC. Boulenger de Hauteclocque A, et al. Among authors: roupret m. BJU Int. 2023 Aug;132(2):160-169. doi: 10.1111/bju.15959. Epub 2023 Feb 1. BJU Int. 2023. PMID: 36648124
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.
Pfister C, Harter V, Allory Y, Radvanyi F, Culine S; VESPER Trial Investigators. Pfister C, et al. Contemp Clin Trials Commun. 2020 Jan 30;17:100536. doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar. Contemp Clin Trials Commun. 2020. PMID: 32083220 Free PMC article.
Oncocytoma on renal mass biopsy: is it still the same histology when surgery is performed? Results from UroCCR-104 study.
Branger N, Bigot P, Pignot G, Lorusso V, Audenet F, Parier B, Doumerc N, Brenier M, Xylinas E, Boissier R, Rouprêt M, Champy C, Nouhaud FX, Lang H, Charles T, Mallet R, Ambrosetti D, Bensalah K, Bernhard JC. Branger N, et al. Among authors: roupret m. World J Urol. 2023 Feb;41(2):483-489. doi: 10.1007/s00345-022-04261-3. Epub 2023 Jan 12. World J Urol. 2023. PMID: 36633650
Nephrectomy for kidney tumour increases the risk of de novo arterial hypertension.
Bigot P, Bernhard JC, Khene ZE, Dariane C, Lebdai S, Doumerc N, Nouhaud FX, Ouzaid I, Saulnier P, Méjean A, Roupret M, Bensalah K; French Committee of Urologic Oncology. Bigot P, et al. Among authors: roupret m. BJU Int. 2023 Nov;132(5):575-580. doi: 10.1111/bju.16124. Epub 2023 Jul 26. BJU Int. 2023. PMID: 37433580
Post-chemotherapy robot-assisted retroperitoneal lymph node dissection for metastatic germ cell tumors: safety and perioperative outcomes.
Branger N, Bladou F, Verhoest G, Knipper S, Robert G, Bernhard JC, Beauval JB, Khaddad A, Mauger De Varennes A, Fléchon A, Walz J, Bageot AS, Doumerc N, Rouprêt M, Murez T; French AFU Testicular Cancer Committee. Branger N, et al. Among authors: roupret m. World J Urol. 2023 Sep;41(9):2405-2411. doi: 10.1007/s00345-023-04536-3. Epub 2023 Jul 28. World J Urol. 2023. PMID: 37507528
Clinical trial protocol for P-NeLoP: a randomized controlled trial comparing the feasibility and outcomes of robot-assisted partial nephrectomy with low insufflation pressure using AirSeal versus standard insufflation pressure (UroCCR no. 85 study).
Margue G, Bigot P, Ingels A, Roupret M, Waeckel T, Long JA, Pignot G, Bensalah K, Lang H, Olivier J, Bruyere F, Durand M, Beauval JB, Mallet R, Parier B, De La Taille A, Bernhard JC. Margue G, et al. Among authors: roupret m. Trials. 2023 Aug 19;24(1):545. doi: 10.1186/s13063-023-07533-4. Trials. 2023. PMID: 37596613 Free PMC article.
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21. Lancet Oncol. 2024. PMID: 38142702 Clinical Trial.
Preparing for the Worst: Management and Predictive Factors of Open Conversion During Minimally Invasive Renal Tumor Surgery (UroCCR-135 Study).
Branger N, Doumerc N, Waeckel T, Bigot P, Surlemont L, Knipper S, Pignot G, Audenet F, Bruyère F, Fontenil A, Parier B, Champy C, Rouprêt M, Patard JJ, Henon F, Fiard G, Guillotreau J, Beauval JB, Michel C, Bernardeau S, Taha F, Mallet R, Panthier F, Guy L, Vignot L, Khene ZE, Bernhard JC. Branger N, et al. Among authors: roupret m. Eur Urol Open Sci. 2024 Mar 28;63:89-95. doi: 10.1016/j.euros.2024.03.009. eCollection 2024 May. Eur Urol Open Sci. 2024. PMID: 38585592 Free PMC article.
1,014 results